You are here

Press Releases from AlphaMed Press

Comment

Discuss

Embargo Policy: Articles for STEM CELLS and STEM CELLS Translational Medicine are embargoed for release until 9 a.m. Eastern U.S. time on the day the article is posted online. This policy applies to members of the media, authors, institutions' public information officers, and the public. Authors may not discuss their work with the media until 1 week before the mailing date or 1 week before online posting of the article, whichever is earlier, and must ensure that the media representatives agree to abide by the embargo policy. STEM CELLS Translational Medicine may refuse to publish a manuscript, despite acceptance for publication, if it has been prematurely released to the press.

July 3, 2018

Depriving stem cells of oxygen and forming them into spheroids before using them to treat bone defects increases their ability to form new bone and repair existing bone, according to a new study in STEM CELLS.

The study was led by Kent Leach, Ph.D., a professor of Biomedical Engineering and Orthopaedic Surgery at the University of California, Davis. “Cell-based approaches for musculoskeletal tissue repair are limited by poor cell survival and engraftment,” he said. “Cells are initially delivered to harsh environments that lack oxygen. We already knew that short-term hypoxic (low oxygen levels) preconditioning of mesenchymal stem cells (MSCs) can prolong cell viability in lab culture, while forming the MSCs into spheroids increases cell survival, trophic factor secretion and tissue formation in vivo.

May 10, 2018

Scientists might be close to a breakthrough in finding a treatment for a severe and devastating skin blistering disease. In a study recently published in STEM CELLS Translational Medicine (SCTM), the team details how they used a certain type of stem cells to significantly relieve the symptoms of recessive dystrophic epidermolysis bullosa (RDEB) in mice.

Mitchell S. Cairo, M.D.

May 4, 2018

Anna D. Krasnodembskaya, Ph.D., has been named STEM CELLS’ Young Investigator of 2017 for her investigations into stem cell-based therapies for acute respiratory distress syndrome (ARDS). The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in STEM CELLS that is deemed to have the most impact and to push the boundaries of novel and insightful research.

April 30, 2018

A long-term study of patients who received stem cells to treat angiitis-induced critical limb ischemia (AICLI) shows the cells to be both safe and effective. The study, published in STEM CELLS Translational Medicine (SCTM), could lead to an option for those who suffer from this serious form of peripheral arterial disease (PAD).

March 29, 2018

A new line of human stem cells shows promise for one day advancing treatment for epileptic seizures. As reported in STEM CELLS Translational Medicine (SCTM), the cells are designed to deliver adenosine – which calms down overexcited neurons and protects them from damage -- to the central nervous system (CNS). The research was conducted by scientists at the University of Bonn and the Central Institute of Mental Health (CIMH) in Mannheim.

March 27, 2018

Smoking dramatically decreases the regenerative ability of stem cells, according to a study recently published in the journal STEM CELLS. These findings suggest that a smoker in need of stem cell therapy might fare better if the cells he receives are donated by a nonsmoker — counter to the alternative approach of using the patient’s own stem cells whenever possible to reduce the chance of rejection.

March 13, 2018

A new study appearing in STEM CELLS Translational Medicine demonstrates the promise of a type of cell found in the placenta in helping those suffering from painful and life-threatening severe acute graft-versus-host disease (GvHD). GvHD occurs in up to 70 percent of patients who have undergone a stem cell transplant to treat a disease such as leukemia, using cells other than their own. GvHD develops because the donor's immune cells attack the patient's normal cells.

February 12, 2018

A new study appearing in STEM CELLS Translational Medicine (SCTM) shows how understanding the way a type of molecule called CD133 functions might contribute to an understanding of the mechanisms involved in kidney repair.

Kidney injuries affect up to 7 percent of hospitalized patients, with those in intensive care especially vulnerable. An increasing amount of evidence indicates that although the kidney might seem to regain normal function, in fact it remains permanently damaged.

Studies conducted on mice have shown that stem cell therapy is a possible path to total kidney repair. That's why scientists are interested in the CD133 molecule.

January 25, 2018

STEM CELLS Translational Medicine (SCTM) named Philippe Lysy, M.D., Ph.D., the STEM CELLS Translational Medicine’s Young Investigator of 2017 for his exploration of new sources of cells capable of conversion into insulin-secretors. The award fosters advancements in the field of stem cells and regenerative medicine by honoring a young researcher who is principle author of an article published in SCTM that is deemed to have the most impact and to push the boundaries of novel and insightful research.

Philippe Lysy,
M.D., Ph.D.

October 24, 2017

In a new study published in STEM CELLS Translational Medicine, researchers used a type of platelet-derived growth factor called PDGF-BB that enhances cells’ ability to regenerate dentin-pulp complex.

Many in the medical community view stem cell therapy as a promising new strategy for repairing teeth once thought to be irreversibly damaged by tooth decay or dental injuries. The benefits of human dental pulp stem cells (hDPSCs), isolated from the living connective tissue in the tooth’s center, on such damage have been well documented in studies.

Pages